Practice makes perfect as Zurich's Simulands receives €10 million

Founded in 2019, Simulands is scaling up having already lured business from leading biotech names Abbott Laboratories, Boston Scientific and Edwards Lifesciences.
Practice makes perfect as Zurich's Simulands receives €10 million

Simulands, a Swiss creator of simulation devices for cardiovascular medicine, recently obtained €10 million to give cardiologists sound training that's appropriate for the mission-critical nature of their field.

The funding is being supplied by healthcare private equity firm SHS, investing from its recently launched sixth fund vintage to accelerate Simulands' commercialisation plans for its cardiac intervention training equipment.

Simulands' portable device replicates pathological anatomy — parts of the cardiovascular system prone to disease — using novel materials and additive manufacturing to mirror real-world patient scenarios.

The devices read out to digital software on a display in the theatre room, including a virtual replica of the cardio vascular system operated via a tablet-sized device by the trainee. Among clients, Simulands already works with teaching hospitals in Switzerland, Germany and the US.

These are medical grade, ISO-compliant simulators with all devices equipped with real haptic responses, procedural imaging, contextual intelligence on performance and various settings to account for varying levels of experience and knowledge.

A safe training environment is absolutely vital to reduce stress for trainee physicians. Confidence in their technique ultimately will lead to better procedural outcomes and patient safety.

Simulands was founded in 2019 in its native Zurich since then adding an impressive clientele that includes leading medtech companies Abbott Laboratories, Boston Scientific and Edwards Lifesciences.

Commenting from SHS's side of the deal, investment partner Dr. Cornelius Maas said: "With the investment into Simulands AG, we are pleased to make our first investment from our newly launched sixth fund generation

"It is very important to us to support the company in its efforts to optimise cardiological interventions for both - doctors and patients. With our investment, we specifically want to drive the expansion of the product portfolio as well as the international expansion. For our new fund, we seek for further innovative, fast-growing healthcare companies that can make a real difference in healthcare."

Andrea Guidotti, Simulands CEO, added: "Technological and scientific innovations are advancing the practice of medicine and augmenting physicians’ capabilities. We should rethink medical education, offering physicians new tools and approaches for continued learning and on-demand training, tailored to physician’s needs and focused on their roles and required skills."

Follow the developments in the technology world. What would you like us to deliver to you?
Your subscription registration has been successfully created.